How Eli Lilly and Company is positioning VERVE-102 at the center of cardiovascular gene editing
Can Eli Lilly and Company’s VERVE-102 transform cholesterol treatment through one-time gene editing? Explore the risks, data, and implications.
Pharma & Biotech
Pharma & Biotech
Merck may have solved the hidden problem behind the oral PCSK9 race
Oral PCSK9 drugs need more than strong LDL data. Merck’s enlicitide paper tests whether peptide manufacturing can scale.
Pharma & Biotech
How Chiesi Global Rare Diseases is positioning lomitapide for earlier lifecycle management in HoFH
CHMP backs paediatric lomitapide for HoFH. Read what this means for clinicians, regulators, and rare disease access across Europe.